Second-line therapy for advanced pancreatic cancer: A review of the literature and future directions
Author:
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference73 articles.
1. Cancer statistics 2009;Jemal;CA Cancer J Clin,2009
2. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials;Heinemann;Semin Oncol,2002
3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997
4. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM–CAP) in patients with advanced pancreatic cancer. Eur J Cancer 2005;3 [abstract PS11].
5. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial;Louvet;J Clin Oncol,2005
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights;World Journal of Gastroenterology;2023-07-07
2. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer;Gut and Liver;2020-01-15
3. Radiofrequency electric field hyperthermia with gold nanostructures: role of particle shape and surface chemistry;Artificial Cells, Nanomedicine, and Biotechnology;2017-09-10
4. Post-gemcitabine therapy for patients with advanced pancreatic cancer – A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens;Cancer Treatment Reviews;2016-11
5. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience;Medical Oncology;2016-03-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3